Table 5.
Multivariate analysis of our prognostic model and traditional clinicopathological parameters for DMFS in HR−/HER2+ breast cancer
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
| No. of patients (no. of events) | 104 (28) | 104 (28) | ||||
| Risk score | 2.36 | (1.48–3.78) | <0.001 | 2.49 | (1.46–4.24) | 0.001 |
| Histologic grade | ||||||
| 1 and 2 | 1.00 | 1.00 | ||||
| 3 | 1.27 | (0.50–3.21) | 0.618 | 1.79 | (0.69–4.65) | 0.229 |
| Lymph node status | ||||||
| Negative | 1.00 | 1.00 | ||||
| Positive | 1.87 | (0.88–3.96) | 0.101 | 1.67 | (0.71–3.91) | 0.238 |
| Tumor size (cm) | 0.211 | 0.155 | ||||
| ≤2 | 1.00 | 1.00 | ||||
| 2–5 | 2.39 | (0.90–6.35) | 0.081 | 2.85 | (0.94–8.61) | 0.063 |
| >5 | 1.68 | (0.32–8.64) | 0.538 | 1.44 | (0.25–8.35) | 0.684 |
Hazard ratios with P values < 0.05 are marked in bold
CI confidence interval